Insmed Inc (INSM)

[allthewaytothebank]

Nice insider buying lately...

2002-11-12 WHITCOMB, RANDALL W.
Director 10,000 Purchase at $0.52 - $0.54 per share.

2002-11-12 ALLAN, GEOFFREY
Chairman 36,200 Purchase at $0.49 per share.

2002-11-08 ALLAN, GEOFFREY
Chairman 2,725 Purchase at $0.44 per share.

2002-10-31 BVF PARTNERS LP
Beneficial Owner (10% or more) *34,600 Purchase at $0.437 per share.

2002-10-15 CROOKE, GRAHAM K.
Director 10,000 Purchase at $0.35 per share.

2002-10-15 ALLAN, GEOFFREY
Chairman 32,500 Purchase at $0.35 per share.

2002-10-14 ALLAN, GEOFFREY
Chairman 12,500 Purchase at $0.37 per share.

2002-10-11 WHITCOMB, RANDALL W.
Director 20,000 Purchase at $0.37 - $0.38 per share.

2002-10-11 ALLAN, GEOFFREY
Chairman 77,500 Purchase at $0.37 per share.

2002-10-10 ALLAN, GEOFFREY
Chairman 100,000 Purchase at $0.35 per share.

2002-10-09 ALLAN, GEOFFREY
Chairman 52,500 Purchase at $0.35 per share.


WASHINGTON (Dow Jones)--Biotechnology Value Fund II LP increased its stake in Insmed Inc. (INSM) to 10%, according to an amended Schedule 13G filing Wednesday with the Securities and Exchange Commission.

The investment group reported owning 3.33 million shares of Insmed common stock as of Oct. 16.

A prior filing indicated the fund held a 6.5% stake, or about 2.14 million shares, in September.

A Schedule 13G denotes a passive investment stake in a company. Filers aren't required to provide a reason for any changes in stake and aren't required to detail any transactions.

Insmed, Richmond, Va., develops treatments for metabolic and endocrine-related conditions.


-Christopher Scinta; Dow Jones Newswires; 202-628-7699; [e-mail]